Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum.

Therriault J, Wang S, Mathotaarachchi S, Pascoal TA, Parent M, Beaudry T, Shin M, Al B, Kang MS, Ng KP, Dansereau C, Park MTM, Fonov V, Carbonell F, Zimmer E, Chakravarty MM, Bellec P, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2019 Jun 22. doi: 10.1007/s12035-019-01671-0. [Epub ahead of print]

PMID:
31230260
2.

No apparent effect of naproxen on CSF markers of innate immune activation.

Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group.

Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun.

3.

Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.

Miron J, Picard C, Lafaille-Magnan MÉ, Savard M, Labonté A, Breitner J, Rosa-Neto P, Auld D, Poirier J; PREVENT-AD research group.

Alzheimers Dement. 2019 Jun 4. pii: S1552-5260(19)30087-1. doi: 10.1016/j.jalz.2019.03.012. [Epub ahead of print]

PMID:
31175027
4.

Aβ-induced vulnerability propagates via the brain's default mode network.

Pascoal TA, Mathotaarachchi S, Kang MS, Mohaddes S, Shin M, Park AY, Parent MJ, Benedet AL, Chamoun M, Therriault J, Hwang H, Cuello AC, Misic B, Soucy JP, Aston JAD, Gauthier S, Rosa-Neto P.

Nat Commun. 2019 Jun 4;10(1):2353. doi: 10.1038/s41467-019-10217-w.

5.

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.

Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G.

Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w.

6.

First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.

Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy JP, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR, Wängler C, Wängler B, Bartenstein P, Bernard-Gauthier V, Schirrmacher R.

ACS Chem Neurosci. 2019 Apr 29. doi: 10.1021/acschemneuro.9b00144. [Epub ahead of print]

PMID:
31017386
7.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
8.

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.

Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan MÉ, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group.

Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5.

9.

PET imaging of freely moving interacting rats.

Miranda A, Kang MS, Blinder S, Bouhachi R, Soucy JP, Aliaga-Aliaga A, Massarweh G, Stroobants S, Staelens S, Rosa-Neto P, Verhaeghe J.

Neuroimage. 2019 May 1;191:560-567. doi: 10.1016/j.neuroimage.2019.02.064. Epub 2019 Mar 2.

10.

Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation.

Liu J, Wang Q, Jing D, Gao R, Zhang J, Cui C, Qiao H, Liang Z, Wang C, Rosa-Neto P, Wu L, Jia J, Gauthier S.

J Alzheimers Dis. 2019;68(2):551-558. doi: 10.3233/JAD-181108.

PMID:
30814350
11.

Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults.

Sheynin Y, Chamoun M, Baldwin AS, Rosa-Neto P, Hess RF, Vaucher E.

Front Neurosci. 2019 Jan 31;13:22. doi: 10.3389/fnins.2019.00022. eCollection 2019.

12.

Machine Learning in Nuclear Medicine: Part 1-Introduction.

Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, Bénard F, Black SE, Zukotynski K.

J Nucl Med. 2019 Apr;60(4):451-458. doi: 10.2967/jnumed.118.223495. Epub 2019 Feb 7. Review.

PMID:
30733322
13.

Constrained instruments and their application to Mendelian randomization with pleiotropy.

Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JB, Greenwood CMT; and for the Alzheimer’s Disease Neuroimaging Initiative.

Genet Epidemiol. 2019 Jun;43(4):373-401. doi: 10.1002/gepi.22184. Epub 2019 Jan 12.

14.

Astrocyte Biomarkers in Alzheimer's Disease.

Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.

Trends Mol Med. 2019 Feb;25(2):77-95. doi: 10.1016/j.molmed.2018.11.006. Epub 2019 Jan 2. Review.

PMID:
30611668
15.

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.

Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G, Mahringer A, Rosa-Neto P, Schirrmacher E, Wängler C, Wängler B, Thiel A, Soucy JP, Bernard-Gauthier V.

Pharmaceuticals (Basel). 2019 Jan 3;12(1). pii: E7. doi: 10.3390/ph12010007. Review.

16.

In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy.

Lam J, DuBois JM, Rowley J, González-Otárula KA, Soucy JP, Massarweh G, Hall JA, Guiot MC, Rosa-Neto P, Kobayashi E.

Ann Neurol. 2019 Feb;85(2):218-228. doi: 10.1002/ana.25404. Epub 2019 Jan 20.

PMID:
30597619
17.

A simplified radiosynthesis of [18 F]MK-6240 for tau PET imaging.

Hopewell R, Ross K, Kostikov A, Pascoal TA, Alberti T, Lacatus-Samoila M, Soucy JP, Bennacef I, Kobayashi E, Kang MS, Rosa-Neto P, Massarweh G.

J Labelled Comp Radiopharm. 2019 Feb;62(2):109-114. doi: 10.1002/jlcr.3695. Epub 2018 Dec 19.

PMID:
30426529
18.

Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.

Schilling LP, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, de Mello Rieder CR, Gauthier S, Palmini A, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2018 Nov 9. doi: 10.1007/s12035-018-1405-1. [Epub ahead of print]

PMID:
30414086
19.

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.

Zhang H, Ng KP, Therriault J, Kang MS, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Transl Neurodegener. 2018 Sep 10;7:23. doi: 10.1186/s40035-018-0127-7. eCollection 2018.

20.

The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia.

Ng KP, Chiew HJ, Lim L, Rosa-Neto P, Kandiah N, Gauthier S.

Expert Rev Neurother. 2018 Nov;18(11):859-869. doi: 10.1080/14737175.2018.1532792. Epub 2018 Oct 10.

PMID:
30286681
21.

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.

Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2018 Aug 16;10(1):80. doi: 10.1186/s13195-018-0407-6.

22.

Optimal use of cholinergic drugs in Alzheimer's disease.

Gauthier S, Herrmann N, Rosa-Neto P.

Brain. 2018 Sep 1;141(9):e68. doi: 10.1093/brain/awy204. No abstract available.

PMID:
30084978
23.

In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KP, Hopewell R, Bouhachi R, Hsiao HH, Benedet AL, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P.

Alzheimers Res Ther. 2018 Jul 31;10(1):74. doi: 10.1186/s13195-018-0402-y.

24.

Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress.

Guadagno A, Kang MS, Devenyi GA, Mathieu AP, Rosa-Neto P, Chakravarty M, Walker CD.

Brain Struct Funct. 2018 Nov;223(8):3711-3729. doi: 10.1007/s00429-018-1720-3. Epub 2018 Jul 21.

PMID:
30032360
25.

PET/CT of Dementia.

Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella AP, Subramaniam RM, Black SE.

AJR Am J Roentgenol. 2018 Aug;211(2):246-259. doi: 10.2214/AJR.18.19822. Epub 2018 Jun 27. Review.

PMID:
29949415
26.

Test-retest variability of [11 C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans.

Smart K, Cox SML, Nagano-Saito A, Rosa-Neto P, Leyton M, Benkelfat C.

Synapse. 2018 Sep;72(9):e22041. doi: 10.1002/syn.22041. Epub 2018 Jul 20.

PMID:
29935121
27.

Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P.

Transl Neurodegener. 2018 May 31;7:12. doi: 10.1186/s40035-018-0117-9. eCollection 2018. Review.

28.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887.

29.

Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.

Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P.

J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924. Review.

30.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

31.

CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.

Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang MS, Gauthier S, Rouleau GA, Poirier J, Bennett DA, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurol Genet. 2018 Jan 30;4(1):e216. doi: 10.1212/NXG.0000000000000216. eCollection 2018 Feb.

32.

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.

Therriault J, Ng KP, Pascoal TA, Mathotaarachchi S, Kang MS, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 Mar 13;90(11):e932-e939. doi: 10.1212/WNL.0000000000005120. Epub 2018 Feb 14.

33.

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1021-1030. doi: 10.1007/s00259-018-3933-3. Epub 2018 Feb 2.

34.

Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.

Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nóbrega OT.

Exp Gerontol. 2018 Jul 1;107:169-177. doi: 10.1016/j.exger.2018.01.002. Epub 2018 Jan 4. Review.

PMID:
29307736
35.

Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.

Bernard-Gauthier V, Mossine AV, Mahringer A, Aliaga A, Bailey JJ, Shao X, Stauff J, Arteaga J, Sherman P, Grand'Maison M, Rochon PL, Wängler B, Wängler C, Bartenstein P, Kostikov A, Kaplan DR, Fricker G, Rosa-Neto P, Scott PJH, Schirrmacher R.

J Med Chem. 2018 Feb 22;61(4):1737-1743. doi: 10.1021/acs.jmedchem.7b01607. Epub 2018 Jan 5.

PMID:
29257860
36.

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.

Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group.

Hum Brain Mapp. 2018 Feb;39(2):971-984. doi: 10.1002/hbm.23897. Epub 2017 Nov 21.

PMID:
29164798
37.

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.

Li X, Ba M, Ng KP, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.

Alzheimers Dement (Amst). 2017 Sep 5;10:12-21. doi: 10.1016/j.dadm.2017.08.001. eCollection 2018.

38.

Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.

Parent MJ, Zimmer ER, Shin M, Kang MS, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Do Carmo S, Dea D, Poirier J, Soucy JP, Gauthier S, Cuello AC, Rosa-Neto P.

J Neurosci. 2017 Dec 13;37(50):12263-12271. doi: 10.1523/JNEUROSCI.1346-17.2017. Epub 2017 Nov 2.

39.

Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.

Gauthier S, Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedetti AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P.

Neurology. 2017 Oct 31;89(18):1931. doi: 10.1212/WNL.0000000000004593. No abstract available.

PMID:
29084927
40.

The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.

Ba M, Li X, Ng KP, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2017 Feb 9;3(1):107-113. doi: 10.1016/j.trci.2016.12.005. eCollection 2017 Jan.

41.

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.

Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.

J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545.

42.

Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA.

Mol Psychiatry. 2017 Nov;22(11):1531-1538. doi: 10.1038/mp.2017.183. Epub 2017 Sep 12.

PMID:
28894304
43.

Identifying incipient dementia individuals using machine learning and amyloid imaging.

Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MS, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2017 Nov;59:80-90. doi: 10.1016/j.neurobiolaging.2017.06.027. Epub 2017 Jul 11.

44.

A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.

Bernard-Gauthier V, Bailey JJ, Mossine AV, Lindner S, Vomacka L, Aliaga A, Shao X, Quesada CA, Sherman P, Mahringer A, Kostikov A, Grand'Maison M, Rosa-Neto P, Soucy JP, Thiel A, Kaplan DR, Fricker G, Wängler B, Bartenstein P, Schirrmacher R, Scott PJH.

J Med Chem. 2017 Aug 24;60(16):6897-6910. doi: 10.1021/acs.jmedchem.7b00396. Epub 2017 Jul 21.

PMID:
28696690
45.

Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.

Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28.

46.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

47.

Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease.

Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL.

IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768. doi: 10.1109/TMI.2017.2693978. Epub 2017 Apr 12.

PMID:
28422655
48.

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.

Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedet AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P, Gauthier S; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2017 May 9;88(19):1814-1821. doi: 10.1212/WNL.0000000000003916. Epub 2017 Apr 12.

49.

Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking.

Chamoun M, Huppé-Gourgues F, Legault I, Rosa-Neto P, Dumbrava D, Faubert J, Vaucher E.

Front Hum Neurosci. 2017 Mar 21;11:128. doi: 10.3389/fnhum.2017.00128. eCollection 2017.

50.

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.

Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P.

Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.

Supplemental Content

Loading ...
Support Center